Debridement

Innovative Outcomes (OTC:UBQU) Announces Distribution Agreement With MDM Wound Ventures to Distribute New EZE Debride System to Healthcare Professionals in 4.95 Billion Dollar Market

Retrieved on: 
Friday, April 5, 2024
Growth, Debridement, EZE, Patient, MDM, Insurance, OTC, CO, Compound annual growth rate, Nursing

Wound Debriding is the process of removing dead tissue in and around wounds and is vitally important to the healing and long-term care of wound care patients.

Key Points: 
  • Wound Debriding is the process of removing dead tissue in and around wounds and is vitally important to the healing and long-term care of wound care patients.
  • In addition, proper in-home wound Debriding cuts down on doctor visits saving money for patients and the healthcare system and helps facilitate faster healing giving patients greater flexibility in their own wound care progress.
  • Insurance companies require all wounds to have a debridement performed (removal of non-viable tissue) to qualify for insurance reimbursement of wound care dressings.
  • Follow Ubiquitech Software Corp, Inc. to learn more about Innovative Outcomes and stay informed about Company developments and growth:

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Retrieved on: 
Friday, March 22, 2024
Nephrotoxicity, Urinary tract infection, Fungal infection, Culture, Ventilator-associated pneumonia, Burns, Internal medicine, Amphotericin B, Emphysema, Azole, Coronary artery disease, Debridement, Carcinoma, Risk, Hyperlipidemia, Patient, Lung, LNC, Fusarium, Female, Malignancy, University, Doctor of Philosophy, MD, Aspergillosis, Echinocandin, Fever, Immune system, Division, Hypertension, Voriconazole, Physician, Infection, Pharmaceutical industry

The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.

Key Points: 
  • The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.
  • She was transitioned to oral MAT2203 for two weeks, which led to clinical resolution of her fungal infection.
  • She began to show clinical improvement following two weeks of oral MAT2203 treatment and her skin wounds completely healed following six months of MAT2203 treatment.
  • “MAT2203 continues to demonstrate its potential to effectively treat invasive fungal infections and help patients achieve complete clinical resolution.

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection

Retrieved on: 
Wednesday, March 13, 2024
USP, Infection, Debridement, Hip, Genetically modified bacteria, Surgeon, Wound healing, Orthopedic surgery, Traumatology

KEELE, England, March 13, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the approval in Brazil of STIMULAN as a calcium matrix antibiotic carrier for use in wound healing and the treatment of bacterial infection.

Key Points: 
  • Brazil joins a growing list of more than 60 countries around the world where STIMULAN is the only calcium matrix approved to carry antibiotics in bone and soft tissue.
  • This approval gives surgeons in Brazil, a country of 217 million people, the flexibility to select and source their preferred choice of antibiotic to suit each patient-specific treatment plan.
  • STIMULAN enables high concentrations of antibiotic to be applied at the point of infection, leading to reduced rates of reinfection, decreased hospital readmissions, and significantly improved patient outcomes.
  • We use STIMULAN concomitantly with the antibiotic vancomycin to completely fill the bone lesion, following debridement, and close with full soft tissue coverage."

SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal

Retrieved on: 
Monday, March 4, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, VLU, Doctor of Philosophy, Nature Reviews Disease Primers, MD, Wound healing, MBA, INN, University, Safety, Mouth ulcer, Element, Debridement, Patient, Phase, Infection, Human, Medical device

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase (provisional INN), a recombinant enzyme derived from medical maggots, which aims to promote wound healing through debridement and wound bed preparation.

Key Points: 
  • SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase (provisional INN), a recombinant enzyme derived from medical maggots, which aims to promote wound healing through debridement and wound bed preparation.
  • The Phase IIa data, which demonstrates proof-of-concept and safety of Aurase Wound Gel in humans, has now been peer-reviewed and published, providing strong validation as SolasCure progresses into further clinical studies, and marks a significant milestone for the Company.
  • SolasCure’s CLEANVLU Phase IIa trial was performed in venous leg ulcer (VLU) patients across centers in the US, UK, and Hungary.
  • The trial compared five escalating dose concentrations to baseline the use of tarumase for enzymatic debridement and wound bed preparation.

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Retrieved on: 
Monday, February 12, 2024
Incidence, FDA, EWMA, Safety, Debridement, Wound, WBP, Patient, Symposium, WHS, Granulation tissue, Disease, SAWC, NSS, European Wound Management Association, Wound healing

SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.

Key Points: 
  • SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.
  • Ofer Gonen, CEO of MediWound said, “These head-to-head results position EscharEx to become the market leader in enzymatic agents for the treatment of chronic wounds.
  • All are achieved within a short time frame to facilitate early wound closure, a major benefit for patients suffering from chronic non-healing wounds.
  • The incidence of achieving WBP throughout the study was 78.3% (95% CI = 63.6-89.1) for EscharEx vs. 37.5% for SANTYL (95% CI=8.5-75.5); p=0.03.

Younger Age of Primary ACL Injury, Decreased Time to Return to Sport Significantly Increases Risk of Secondary ACL Injury in Adolescent Athletes

Retrieved on: 
Monday, February 12, 2024
Anterior cruciate ligament injury, SAN, Outline, Adolescence, Arthrofibrosis, Education, Cleveland Browns, Injury, Database, RTS, Infection, Sport, Risk, Prevalence, ACL, Debridement, Summative assessment, Patient, Athlete, Rehabilitation, Anterior cruciate ligament reconstruction, Literature, AAOS, Ligament, American Academy

The study, "Predictors of Anterior Cruciate Ligament Reinjury and Return to Sport in Adolescent Athletes," found that when the age of primary ACLR increases by one year, the rate of secondary ACL injury decreases by 29% and a one-month delay in RTS decreases the rate of a secondary ACL injury by 17%.

Key Points: 
  • The study, "Predictors of Anterior Cruciate Ligament Reinjury and Return to Sport in Adolescent Athletes," found that when the age of primary ACLR increases by one year, the rate of secondary ACL injury decreases by 29% and a one-month delay in RTS decreases the rate of a secondary ACL injury by 17%.
  • ACL injuries in adolescent athletes are increasing mainly due to the rise of younger athletes playing in competitive sports at an earlier age and an increased awareness of ACL injuries.
  • [iv]
    The researchers sought to identify recent epidemiologic trends of ACL injuries and recurrent tear rates in high school athletes, and determine variables related to sustaining a secondary ACL injury.
  • After adjusting for all variables, a younger age at primary ACLR and time to RTS were significantly associated with an increased rate of secondary ACL injury.

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Retrieved on: 
Thursday, December 21, 2023
Phase, Mortality, Mouth ulcer, Ulcer, Debridement, Amputation, Effect, Granulation tissue

Results show that EscharEx not only effectively debrides wounds, but also reduces biofilm and bacterial load in both VLUs and DFUs.

Key Points: 
  • Results show that EscharEx not only effectively debrides wounds, but also reduces biofilm and bacterial load in both VLUs and DFUs.
  • 70% of the patients (7/10) that completed the study achieved complete debridement within a median time of 5.5 days.
  • An average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period.
  • Together with the outcomes of our previous Phase II study results, this study furthers the understanding of the effects of EscharEx.

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

Retrieved on: 
Monday, November 13, 2023
Safety, European Medicines Agency, European Commission, Incidence, Bromelain (pharmacology), EMA, Civil service commission, Patient, Burn, Trauma, CHMP, Committee, Human services, Burns, Development, Debridement, Administration, SOC, Bleeding

The CHMP positive opinion is pending a decision by the European Commission, which is expected imminently.

Key Points: 
  • The CHMP positive opinion is pending a decision by the European Commission, which is expected imminently.
  • It is also supported by additional pediatric data available from Phase 3 and Phase 2 studies conducted during the clinical development of NexoBrid.
  • “This significant milestone advances our goal to redefine the standard of care for the treatment of severe burns.
  • He added, “From a commercial perspective, pediatric burn victims comprise more than 30% of the total burn population making this new indication a significant addition to our addressable market.”